FDA Grants AlgoTx IND Clearance for Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

European biotech AlgoTx announced that the US FDA cleared its Investigational New Drug Application (IND) for Phase II candidate ATX01 in the treatment of Chemotherapy-Induced Peripheral Neuropathy.